

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



re application of: C. Frank Bennett and Susan M. Freier

Title: Antisense Modulation of HKR1 Expression

BOX SEQUENCE  
Assistant Commissioner for Patents  
Washington DC 20231

PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find the following:

- The specification of the above-referenced patent application;
- An executed Declaration or Oath and Power of Attorney;
- An Assignment of the invention to **Isis Pharmaceuticals Inc.** with recordation cover sheet (PTO Form PTO-1595) and \$40.00 cover fee;
- Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR § 1.821 through 1.825;
- Sequence listing in computer readable form in accordance with 37 C.F.R. § 1.821(e);
- An Information Disclosure Statement with references; and
- Applicant claims small entity status pursuant to 37 CFR § 1.27.

The filing fee has been calculated as shown below:

For:	No. Filed	No. Extra	Rate	Fee
BASE FEE				
Total Claims	20 - 20 =	0	X \$9=	\$0
Indep. Claims	2 - 3 =	0	x\$40=	\$0
			TOTAL	\$ 355.00

The Commissioner is hereby authorized to charge the following fees to Deposit Account No. 500252:

- the amount of \$395.00 for the above listed fees;
- payment of the following fees associated with this communication or credit any overpayment;
- any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims; and
- any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20 (d).

Triplicate copies of this transmittal are enclosed.

Date: July 3, 2001

Laurel Spear Bernstein  
Registration No. 37,280  
Isis Pharmaceuticals, Inc.

Please address all correspondence to:

Jane Massey Licata or Kathleen A. Tyrrell  
Licata & Tyrrell, P.C.  
66 East Main Street  
Marlton NJ 08053  
(856) 810-1515